A new study has found that the ARF tumor suppressor gene plays a critical role in slowing the growth of pancreatic ductal adenocarcinoma (PDAC). Researchers showed that many pancreatic tumors disable both ARF and INK4A, two distinct genes often grouped together as CDKN2A.
In mouse models, loss of ARF significantly accelerated pancreatic cancer, even when the p53 tumor suppressor gene was already inactive, revealing that ARF protects against cancer through additional mechanisms.
The study also found that ARF loss changes the tumor environment by increasing collagen production, attracting fibroblasts, and creating dense, stiff tumors that are more resistant to treatment and less accessible to immune cells.
These findings improve understanding of how pancreatic cancer develops and suggest that therapies targeting the biological effects of ARF loss could offer new treatment strategies for patients with PDAC.